Premium
Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post‐hematopoietic stem cell transplant for dyskeratosis congenita due to TINF 2 mutation
Author(s) -
O'Connell Niall,
Goodyer Matthew,
Gleeson Mary,
Storey Lorna,
Williams Martina,
Cotter Melanie,
O'Marcaigh Aengus,
Smith Owen
Publication year - 2014
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12172
Subject(s) - medicine , rituximab , dyskeratosis congenita , mycophenolate , immunology , refractory (planetary science) , hematopoietic stem cell transplantation , antibody , autoimmune hemolytic anemia , transplantation , dna , physics , telomere , biology , astrobiology , genetics
AIHA following allogeneic HSCT is appearing more frequently in the literature. It occurs as a result of donor cell‐derived antibodies targeting donor red cell antigens. Little guidance exists on the management of such patients, particularly in the pediatric setting. First‐line conventional treatment is corticosteroids and/or immunoglobulin therapy with monoclonal antibody therapy reserved for treatment failure. We report our experience of a child refractory to immunoglobulin and steroid therapy who required several infusions of rituximab and immunomodulatory therapy to obtain a clinically significant response.